Medivizor

Title of notification

Here comes the notification
X
 
icon
icon
diabetes mellitus | Research | Treatment | 10 pages | source: Frontiers in Endocrinology | Added Dec 31, 2021

Can combined therapy with sodium-glucose co-transporter 2 inhibitors and sulfonylureas affect the risk of hypoglycemia in patients with type 2 diabetes?

This review assessed the risk of hypoglycemia (dangerously low blood glucose) with the addition of sodium-glucose co-transporter 2 (SGLT-2) inhibitors to sulfonylureas in patients with type 2 diabetes (T2D). The authors concluded that this combination was associated with an increased risk of hypoglycemia.

icon
diabetes mellitus | Research | 10 pages | source: Frontiers in Endocrinology | Added Dec 19, 2021

Can anti-diabetic drug use affect fracture risk in patients with type 2 diabetes?

This study evaluated the safety of anti-diabetic drugs in the risk of fractures based on available data from clinical trials. The data showed differences in associations between the use of anti-diabetic drugs and fracture risk.

icon
icon
diabetes mellitus | Research | Treatment | 10 pages | source: Diabetes, Obesity and Metabolism | Added Nov 21, 2021

How effective is iGlarLixi in patients with uncontrolled type 2 diabetes?

This study evaluated the effectiveness of insulin glargine 100U/ml (iGlar; Lantus) and lixisenatide (Lixi; Lyxumia) combined (iGlarLixi; Soliqua) compared with each of the two drugs alone in patients with type 2 diabetes (T2D) that was uncontrolled with 2 anti-diabetic oral drugs. The data showed that iGlarLixi resulted in better glucose control compared to iGlar or Lixi, and did not cause abnormally low blood glucose (hypoglycemia).

icon
icon
diabetes mellitus | Research | Treatment | 10 pages | source: Lancet (London, England) | Added Nov 02, 2021

Effectiveness and safety of tirzepatide compared to insulin degludec in patients with type 2 diabetes.

This study compared the effectiveness and safety of tirzepatide to insulin degludec (Tresiba) in patients with uncontrolled type 2 diabetes (T2D). The data showed that tirzepatide produced better blood glucose control and body weight improvements with reduced risk of hypoglycemia, compared to degludec in these patients.

icon
diabetes mellitus | Research | 10 pages | source: Diabetes & Metabolism | Added Oct 31, 2021

Improved changes in the eye in patients with type 2 diabetes using dapagliflozin compared to glibenclamide.

This study investigated the change in central retinal thickness (CRT) by optical coherence tomography (OCT) in patients with type 2 diabetes (T2D) after 12 weeks of treatment with dapagliflozin (Farxiga) or glibenclamide (Diabeta). The authors concluded that CRT may improve with short-term use of dapagliflozin compared with glibenclamide treatment.

icon
icon
rheumatoid arthritis | Research | Treatment | 10 pages | source: The Journal of Rheumatology | Added Oct 25, 2021

Impact of 5-year baricitinib treatment for active, rheumatoid arthritis in preventing radiographic progression of joint damage.

This study evaluated the effect of oral baricitinib (Olumiant) on the prevention of radiographic progression of joint damage over 5 years in patients with active rheumatoid arthritis (RA). The data showed that patients treated with oral baricitinib had less radiographic progression over 5 years, compared to those initially given a conventional synthetic disease-modifying antirheumatic drug (csDMARD) and placebo or methotrexate (MTX; Otrexup) alone.

icon
icon
diabetes mellitus | Research | Treatment | 10 pages | source: Endocrine | Added Oct 25, 2021

Do insulin analogues differ in effectiveness and safety for the treatment of diabetes?

This study assessed the effectiveness and safety of different long-acting and short-acting insulins for the treatment of patients with diabetes. The data supported the use of long-acting insulins instead of neutral protamine Hagedorn (NPH) insulin (Humulin N; Novolin N), as basal insulin for patients with type 2 diabetes (T2D).

icon
icon
diabetes mellitus | Research | Treatment | 10 pages | source: Diabetes Research and Clinical Practice | Added Oct 19, 2021

Evaluating kidney and heart benefits of SGLT2 inhibitors for patients with diabetes and kidney disease

This review looked at SGLT2 inhibitor medications for people with both type 2 diabetes (T2D) and chronic kidney disease (CKD). It found that SGLT2 inhibitors reduced worsening of the kidneys for these patients.

icon
icon
diabetes mellitus | Research | Treatment | 10 pages | source: Journal of Diabetes and its Complications | Added Oct 16, 2021

How beneficial are foot-ankle flexibility and resistance exercises for preventing foot diabetic ulcer recurrence?

This study assessed the effect of foot-ankle flexibility and resistance exercises in the prevention and recurrence of plantar foot-diabetic ulcers. The authors concluded that foot-ankle flexibility and resistance exercises can reduce the recurrence of plantar foot-diabetic ulcers and improve diabetic neuropathy (DN; nerve damage) and walking speed.

icon
rheumatoid arthritis | Research | 10 pages | source: Scientific reports | Added Oct 11, 2021

Do biologics increase the risk of blood clots in patients with rheumatoid arthritis?

This study looked at the risk of blood clots in patients with rheumatoid arthritis (RA) treated with biologics. It found that there was no significant increase in the risk of blood clots with biologics compared to other RA treatments.

View

Conditions

Category

  • icon
  • icon
  • icon
  • icon
  • icon
  • icon
  • icon
  • icon
  • icon

Was this helpful?